ESR1 and breast carcinoma: The subtype-specific breast cancer analyses suggested no increased risk of ER+ or ER- breast cancer by moderate or frequent/heavy use of skincare products and no difference in effect by estrogen receptor status (0.58 ≤ pheterogeneity ≤ 0.99, Table 3).